Payment overview · 2025
General Payments
$299.37
17 reported records · 8 companies
Healthcare provider profile · identity verified
Jess E Jordan, APRN
Physician Assistants & Advanced Practice Nursing Providers|Nurse Practitioner|Family · CLARKSVILLE, AR · NPI 1285042259
Verified facts
What the public records show
CMS Open Payments records show Jess E Jordan, APRN received $299.37 in general payments during 2025 across 17 reported records.
ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) accounted for 25.0% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 14 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Ozempic, Rybelsus.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 62 claims for Farxiga by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 69 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Rybelsus by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 78 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $74.79 | 25.0% | 4 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $64.64 | 21.6% | 4 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $47.88 | 16.0% | 3 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $38.25 | 12.8% | 2 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $21.49 | 7.2% | 1 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $20.88 | 7.0% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $16.28 | 5.4% | 1 | 2025 |
| Xeris Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $15.16 | 5.1% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $299.37 | 17 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $74.79 | 4 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $47.88 | 3 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $35.19 | 2 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $35.19 | 2 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $29.45 | 2 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $29.45 | 2 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $29.45 | 2 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC | $21.49 | 1 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $20.88 | 1 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $20.88 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $17.14 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $17.14 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $16.28 | 1 | 2025 |
Source payment records
|
|||||
| GVOKE HYPOPEN Normalized: gvoke hypopen |
Drug | Xeris Pharmaceuticals, Inc. | $15.16 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| Ozempic ozempic |
2025 | Ozempic | 2024 | 69 | exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 12 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
62 | 17 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
69 | 12 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
78 | 11 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
14 | 14 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Rosuvastatin Calcium | Rosuvastatin Calcium | 216 | 51 |
| Pantoprazole Sodium | Pantoprazole Sodium | 204 | 56 |
| Gabapentin | Gabapentin | 164 | 31 |
| Atorvastatin Calcium | Atorvastatin Calcium | 153 | 37 |
| Levothyroxine Sodium | Levothyroxine Sodium | 151 | 37 |
| Prednisone | Prednisone | 139 | 106 |
| Losartan Potassium | Losartan Potassium | 129 | 33 |
| Omeprazole | Omeprazole | 104 | 21 |
| Hydrochlorothiazide | Hydrochlorothiazide | 95 | 18 |
| Amlodipine Besylate | Amlodipine Besylate | 93 | 24 |
| Lisinopril | Lisinopril | 89 | 25 |
| Allopurinol | Allopurinol | 82 | 12 |
| Metoprolol Tartrate | Metoprolol Tartrate | 79 | 18 |
| Eliquis | Apixaban | 78 | 11 |
| Famotidine | Famotidine | 76 | 20 |
| Ezetimibe | Ezetimibe | 75 | 20 |
| Tamsulosin Hcl | Tamsulosin Hcl | 75 | 21 |
| Alprazolam | Alprazolam | 69 | suppressed |
| Ozempic | Semaglutide | 69 | 12 |
| Clopidogrel | Clopidogrel Bisulfate | 67 | 15 |
| Potassium Chloride | Potassium Chloride | 67 | 18 |
| Alendronate Sodium | Alendronate Sodium | 63 | 13 |
| Cefdinir | Cefdinir | 63 | 54 |
| Metformin Hcl | Metformin Hcl | 63 | 20 |
| Farxiga | Dapagliflozin Propanediol | 62 | 17 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 52 | 41 |
| Celecoxib | Celecoxib | 52 | 20 |
| Trazodone Hcl | Trazodone Hcl | 52 | 15 |
| Zolpidem Tartrate | Zolpidem Tartrate | 52 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 51 | 44 |
| Meloxicam | Meloxicam | 51 | 18 |
| Trulicity | Dulaglutide | 51 | suppressed |
| Furosemide | Furosemide | 50 | 17 |
| Jardiance | Empagliflozin | 49 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 49 | 19 |
| Azithromycin | Azithromycin | 47 | 45 |
| Fluticasone Propionate | Fluticasone Propionate | 46 | 24 |
| Mirtazapine | Mirtazapine | 45 | suppressed |
| Metoprolol Succinate | Metoprolol Succinate | 44 | 11 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 43 | 24 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 42 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 42 | 11 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 40 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 38 | suppressed |
| Lorazepam | Lorazepam | 37 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 37 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 35 | suppressed |
| Glipizide | Glipizide | 35 | 13 |
| Entresto | Sacubitril/Valsartan | 34 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 33 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 32 | suppressed |
| Fluconazole | Fluconazole | 31 | 24 |
| Lansoprazole | Lansoprazole | 31 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 31 | suppressed |
| Glipizide Er | Glipizide | 29 | suppressed |
| Carvedilol | Carvedilol | 28 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 26 | 25 |
| Duloxetine Hcl | Duloxetine Hcl | 26 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 26 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 25 | suppressed |
| Atenolol | Atenolol | 24 | suppressed |
| Cephalexin | Cephalexin | 23 | 21 |
| Citalopram Hbr | Citalopram Hydrobromide | 23 | suppressed |
| Montelukast Sodium | Montelukast Sodium | 23 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 22 | 11 |
| Amitriptyline Hcl | Amitriptyline Hcl | 20 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 20 | 15 |
| Simvastatin | Simvastatin | 20 | suppressed |
| Bupropion Xl | Bupropion Hcl | 19 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 19 | 15 |
| Levofloxacin | Levofloxacin | 19 | 14 |
| Mounjaro | Tirzepatide | 19 | suppressed |
| Oseltamivir Phosphate | Oseltamivir Phosphate | 19 | 19 |
| Verapamil Er | Verapamil Hcl | 19 | suppressed |
| Acyclovir | Acyclovir | 18 | suppressed |
| Arexvy | Rsvpref3 Antigen/As01e/Pf | 18 | 18 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 18 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 18 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 17 | suppressed |
| Spironolactone | Spironolactone | 17 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 17 | 16 |
| Clarithromycin | Clarithromycin | 16 | 15 |
| Clonazepam | Clonazepam | 16 | suppressed |
| Torsemide | Torsemide | 16 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 16 | suppressed |
| Valsartan | Valsartan | 16 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 15 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 15 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 15 | suppressed |
| Repatha Sureclick | Evolocumab | 15 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 15 | 13 |
| Belsomra | Suvorexant | 14 | suppressed |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 14 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 14 | 14 |
| Ropinirole Hcl | Ropinirole Hcl | 14 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 13 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 13 | 13 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 13 | suppressed |
| Pregabalin | Pregabalin | 13 | suppressed |
| Sucralfate | Sucralfate | 13 | suppressed |
| Telmisartan | Telmisartan | 13 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 12 | suppressed |
| Cefadroxil | Cefadroxil | 12 | suppressed |
| Methenamine Hippurate | Methenamine Hippurate | 12 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 12 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 12 | suppressed |
| Rybelsus | Semaglutide | 12 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 11 | suppressed |
| Metronidazole | Metronidazole | 11 | 11 |
| Propranolol Hcl Er | Propranolol Hcl | 11 | suppressed |
| Topiramate | Topiramate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $299.37 · 17 records | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | ABRYSVO, AIRSUPRA, CAPLYTA, COMIRNATY, Cologuard Collection Kit, GVOKE HYPOPEN, NURTEC ODT, Ozempic, PREVNAR 20, QULIPTA, REXULTI, Rybelsus, UBRELVY, ZAVZPRET | 5 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Ozempic play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error